Amicus Therapeutics announced the beginning of the availability of Galafold (migalastat) to treat Fabry disease in Japan, making this…
Articles by Ana de Barros, PhD
April is Fabry Disease Awareness Month, and Amicus Therapeutics helped to raise awareness about the disease, as well as Pompe…
Amicus Therapeutics has launched Healing Beyond Disease, an initiative designed to celebrate people living with rare diseases, like Fabry…
Biotechnology companies Shire and NanoMedSyn are collaborating on research to evaluate a potential enzyme replacement therapy (ERT) for…
The U.S. Food and Drug Administration will be giving priority review to Amicus Therapeutics’ Fabry disease therapy Galafold (migalastat). Fabry…
Amicus Therapeutics recently announced the launch of Galafold (migalastat) in Spain for the long-term treatment of anyone who has…
The Canadian Drug Expert Committee (CDEC) has recommended in favor or reimbursement of Galafold (migalastat) for long-term treatment of adults…